Preliminary cost variance modeling to compare autologous intraovarian platelet-rich plasma vs. standard hormone replacement therapy for menopause management

Předběžné modelování odchylky nákladů pro porovnání autologní intraovariální plazmy bohaté na trombocyty a standardní hormonální substituční terapie při menopauze

Úvod: Příznaky menopauzy a hormonální substituční terapie (HRT) patří mezi nejčastější důvody, proč pacientky přichází ke gynekologovi. Ačkoli ve vyspělých zemích v průběhu života HRT užívá nejméně polovina všech žen, s léčbou jsou spojena rizika a doporučené postupy se různí. Větší povědomí o rizicích HRT při dlouhodobém užívání vyvolalo zájem o „bezpečnější alternativy“. Do popředí se tak dostalo zmírnění příznaků menopauzy pomocí autologního intraovariálního podání plazmy bohaté na trombocyty (OPRP), jehož vhodnost a nákladovou efektivitu je však nutné prozkoumat. Metody: Kumulativní roční náklady na pacientku byly na základě údajů o HRT a OPRP z USA porovnány pomocí stochastického modelování metodou Monte Carlo. Výsledky: Střední hodnota ± SD nákladů na pacientku pro HRT, zahrnující úvodní konzultaci a opakované vydání v lékárně, byla odhadnuta jako 576 ± 246 USD za rok. Ačkoli OPRP nemá lékárenskou složku, odhadované 4 návštěvy v průběhu jednoho roku v rámci udržování OPRP zahrnují ultrazvuk, flebotomii / zpracování vzorku, chirurgické vybavení a náklady na inkubaci / laboratoř. Střední hodnota ± SD nákladů pro OPRP byla 8 719 ± 4 911 USD za rok (p < 0,0001 vs. HRT, T-test). Horní hranice odhadu pro roční náklady na HRT a OPRP byla 1 341 USD, resp. 22 232 USD. Závěr: Ačkoli jsou HRT a OPRP v léčbě menopauzy podobně účinné a bezpečné, výrazně se liší v nákladové efektivitě. Pro většinu pacientek by OPRP byla pravděpodobně příliš komplexní, invazivní a drahá na to, aby mohla konkurovat HRT. Ačkoli je OPRP pro vybrané pacientky s menopauzou, které se zdráhají podstoupit HRT, zajímavou a s opatrností i užitečnou metodou, širší použití této léčby neplodnosti se v porovnání se standardními možnostmi HRT, které jsou momentálně na trhu, nezdá být  efektivní.

Klíčová slova:

menopauza – alternativní léčba – plazma bohatá na trombocyty – náklady na zdravotní péči

Authors: Sills S. E. 1,2;  Tan L. S. 3,4
Authors place of work: San Clemente, California, USA ;  Escondido, California, USA ;  Montréal, Quebec, Canada ;  Reproductive Research Section, FertiGen/ CAG 1;  Department of Obstetrics and Gynecology, Palomar Medical Center 2;  OriginElle Fertility Clinic 3;  Department of Obstetrics and Gynecology, McGill University Health Centre 4
Published in the journal: Ceska Gynekol 2022; 87(1): 28-34
Category: Původní práce
doi: 10.48095/cccg202228


Background: Menopause symptoms and hormone replacement therapy (HRT) are among the most common reasons patients seek gynecological advice. Although at least half of all women in developed countries will use HRT during their lifetime, the treatment is not without risk and guidance on HRT is mixed. Greater awareness of HRT risks from extended use has piqued interest in ‘safer options’. Menopause reversal with autologous ovarian platelet-rich plasma (OPRP) has brought this restorative approach forward for consideration, but appropriateness and cost-effectiveness require examination. Methods: HRT and OPRP data from USA were projected to compare cumulative 1yr patient costs using stochastic Monte Carlo modeling. Results: Mean ± SD cost-to-patient for HRT including initial consult plus pharmacy refills was estimated at about $576 ± 246/yr. While OPRP included no pharmacy component, an estimated 4 visits over 1yr for OPRP maintenance entailed ultrasound, phlebotomy/sample processing, surgery equipment, and incubation/laboratory expense, yielding mean ± SD cost for OPRP at $8,710 ± 4,911/yr (P < 0.0001 vs. HRT, by T-test). Upper-bound estimates for annual HRT and OPRP costs were $1,341 and $22,232, respectively. Conclusions: While HRT and OPRP may have similar efficacy and safety for menopause therapy, they diverge sharply in cost-effectiveness. Most patients would likely find OPRP too complex, invasive, and expensive to be competitive vs. HRT. Although OPRP is an interesting and cautiously useful technique for selected menopause patients reluctant to use HRT, repurposing this infertility treatment for wider use appears inefficient compared to standard HRT options that are currently marketed.


menopause – platelet-rich plasma – alternative therapy – health spending


Hormone replacement therapy (HRT) is an important part of menopause care. Without timely intervention, increased risks of cardiovascular disease, osteoporosis, premature cognitive decline and vaginal atrophy can lead to reduced qua­lity-of-life in menopause [1,2]. Synthetic hormone usage in this population was on track for an ever-upward rise, until safety concerns from the Women’s Health Initiative (WHI) emerged in 2002. The global HRT market swiftly collapsed when worrisome results became generally known [3], and promotional spending was cut particularly for those prescriptions most directly implicated inWHI [4]. National data showed diminished HRT sales affected all hormone products across every patient demographic [5], although better-educated patients seemed more inclined to consider alternatives to HRT compared to those with different  academic backgrounds [6].

This market disruption opened an unexpected opportunity for compounded ‘bio­identical hormones’ [7,8] to grow their niche within an economy va­lued at > $20B. These alternative treatments exploited their exempt non-FDA--regulated status to cultivate an image of being safer than conventional HRT, achieving an outsized presence.

In 2016, an infertility treatment termed ‘ovarian rejuvenation’, unrelated to menopause care, was developed in Athens, Greece [9]. This innovation was a corollary to PRP work already successfully applied in other clinical fields, but previously unknown in reproductive bio­logy. The technique involved minor surgery to insert autologous platelet-rich plasma (PRP) into ovarian tissue. Remarkably, case data and small series described healthy pregnancies and deliveries among poor-prognosis patients – some of whom were menopausal [10–12]. Against this landscape, the potential to refit ovarian PRP (OPRP) attracted notice as a way to address symptomatic menopause akin to other alternative therapies. Here we share the first economic appraisal of OPRP for this specific indication.

PRP: Another ‘bio­identical’?

OPRP provides benefits congruent with other ‘bio­identical’ menopause treatments, but patient willingness to consider non-traditional options and altered physician prescribing patterns away from HRT are essential preconditions [13]. There has been a large femi­nist contribution to the sociomedical discourse, rightly rejecting tendencies to manage menopause as one homo­genous condition [14]. The bespoke, personal dimension of OPRP assuages this discontent. One critique decried healthcare providers who continue to ‘let patients down’ with low value me- dical advice, harming not just the patient but also damaging the entire health economy [15]. But for menopause, does OPRP have value?

As ‘self-tissue’ processed fresh prior to each use, autologous platelet-rich plasma derivatives carry intrinsic appeal as a natural, non-synthetic alternative to bulk HRT engineered on an industrial scale. Hypersensitivity reactions are very rare, thought to occur only in response to platelet activators rather than the autologous PRP itself [16]. One study sampled preferences among patients (average age 60.5 yrs) where compounded options were felt to be ‘just as good or better’ than manufactured pharmaceuticals, with > 95% satisfied with everything but the cost [17].

The commercial rise of ’bio­identicals’ has not been restrained by the lack of supporting evidence to prove they are safer or any more effective than HRT [18]. With OPRP, its chief weakness on evidence is that studies to date have not included a control/saline injection group. This could be relevant if simple puncture, capsule stretching, and/or local microtrauma to ovarian tissue triggers temporary inflammatory signaling and improved ovarian function [19]. The assertion that ‘ovarian acupuncture’ could evoke meaningful AMH change was countered by the observation that platelet concentration, not injection itself, relates to AMH response after OPRP treatment [20]. Moreover, when such ‘blank doses’ were studied in an animal model, it was shown that saline injection alone had no effect on ovarian function [21].

General agreement exists that any kind of HRT can reduce bone turnover, slow bone reabsorption, and increase bone mineral density [22], but extant literature on OPRP has not shown any such effect with this procedure. It is plausible OPRP could similarly protect against fracture risk by improving BMD, with the proviso ‘ovarian rejuvenation’ was maintained. This would parallel experience with HRT where evidence shows skeletal benefits are not retained after HRT stops [23].

Most patients coming in for OPRP expect to have both ovaries injected, but this is not always possible. In one series, unplanned unilateral access occurred in about 35% of cases [20]; this usually occurred when higher BMI and poor visibility blocked clear visualization of adnexal structures on ultrasound. Despite heavier patients being less likely to undergo bilateral ovarian injection, sub-group analysis showed injection of just one ovary had similar effects for improved overall sexual experience (P = 0.85), energy level (P = 0.42), and menses recovery (P = 0.15) compared with patients who received bila­teral OPRP [24].


Several HRT routes of administration are available, although the two most popular are oral and transdermal [25], which were selected for this comparison. These main modes of HRT administration are followed by patient-applied topical creams or lotions, chiefly as intravaginal preparations. Conversely, OPRP delivery methods show almost no variation. All ‘ovarian rejuvenation’ relies on resource intensive needle insertion by ultrasound (TV-USG) guidance or laparoscopy to access ovarian tissue. A recent literature review [26] suggests that laparoscopy is uncommonly used for OPRP, unless some prevailing circumstance renders the TV-USG approach unsuitable or unsafe. Accordingly, our calculation included TV-USG only for OPRP.

Since OPRP shares functional overlap with in vitro fertilization (IVF) and ovarian cyst aspiration, related audits [27] were used to guide estimates for OPRP, especially for the initial doctor’s consultation. Economic data were obtained from aggregate U.S. medical charge surveys [25] on single-use surgical equipment and reagents, incubator, laboratory and technical staff costs, as well as published pharmacy estimates for representative prescribed HRT agents (as out-of-pocket cost). To isolate annual estimates for the treatments under study, the model excluded costs incurred outside menopause symptom management.

Comparisons between patient medical costs typically relies on National Inpatient Sample data where cost-to-charge ratios are calculated from Healthcare Cost & Utilization Project figures [28]. However, because OPRP is an outpatient procedure and HRT is medication only, for this analysis cost variance (CVAR) was defined as follows:

CVAR = Ve – Ca


Ve = treatment benefit (earned value)

Ca = actual cost

Due to confined data with both treatments (especially OPRP), costs were considered stochastic to test the net effect on individual patient expenditure. Probabilistic modeling can help reduce epistemic uncertainty when partial data are prevalent. This effect was studied by Monte Carlo simulations (N = 500) iteratively to generate forward modeling. For HRT, input distributions were defined by past and current pharmacy costs, and formulaic assumptions included accept­ing at least one of the current HRT preparations as capable to offer high (or at least adequate) Ve to consumers (patients). This is probably correct given industry data and academic literature indicating a low drop-out rate for HRT [29,30]. In contrast, OPRP is a new arrival with no longitudinal information available on compliance and satisfaction. Early monitoring suggests complications/adverse events with OPRP may be lower than for HRT, so this model considered treatment efficacy as comparable across the two methods studied. Self-pay HRT cost to patients was thus calculated from published pharmacy data to supply product refills for one year, where monthly mean ± SD = $47.50 ± 20. Projecting patient cost for OPRP was by itemizing its two main components (specimen proces­sing + office surgery) which were unbundled, appraised separately then recombined, where mean ± SD = $8,750 ± 5,000. Results were annualized by stochastic analysis using ASTM E1369 v.1.0 (National Institute of Standards &Technology; Gaithersburg, MD) on Microsoft Excel.


Using available published public datasets for office visit costs, administrative and associated laboratory fees, as well as out-of-pocket cost for non-generic HRT, yearly 2021 patient cost was projected at approximately $576 ± 238, with maximum annual HRT spending estimated at $1,340 (Fig. 1). OPRP cost was captured by disaggregating individual elements and then adding the constituent parts to calculate total patient expense. This comprised PRP processing and preparation (CPT 0232T) which was associated with a historic cost per injection of $2,000 [31]. Since that cost was published in 2009, inflation adjustment [32] corrected the per-injection value to the current (2021) equivalency, approximately $2,557. Thus, four PRP samples prepared over 1yr would be about $10,000. The surgical component of OPRP shares equipment and technical overlays with standard ovarian cyst drainage by ultrasound guidance (CPT 58800), where the average cost is $1,875. Experience with OPRP suggests baseline/initial injection appointments require more procedure time, but as ovaries respond (enlarge) in later months, the technical difficulty is reduced using less clinic time. However, this trend is tentative and derived from one California center only, so uniform visit times were used for each visit. This produces a projected cost of $7,500 for planned OPRP series over 1yr. To account for geographic pricing differences, the sum of the two main cost centers was split (50%) and a large ± SD of 5,000 was factored to account for regional fluctuation. Consequently, the annual 2021 patient cost for OPRP was estimated at approximately $8,710 ± 4,911 (P < 0.0001 vs. HRT, by Student’s T-test), with the maximum 4-visit patient cost projected at $22,232.

Fig. 1. Projected annual costs in USD for two menopause treatments, standard (Rx) hormone replacement therapy and
ovarian platelet-rich plasma (P) estimated by Monte Carlo simulations (N = 500). Cumulative spend (yellow line vs. red
line) for HRT was significantly below OPRP (P < 0.0001, by Student’s T-test) and persisted (C’) after adjustment (ADJ)
for shorter-duration OPRP clinic visits (b, c, d). Maximum costs (CMAX) for HRT and OPRP were modeled at ,341 and
,232, respectively.<br>
Obr. 1. Předpokládané roční náklady v USD na dvě léčby menopauzy, standardní (Rx) hormonální substituční terapii a ovariální
plazmu bohatou na krevní destičky (P) odhadnuté pomocí Monte Carlo simulací (n = 500). Kumulativní útrata (žlutá čára
vs. červená čára) za HRT byla významně pod OPRP (p < 0,0001, Studentovým T-testem) a přetrvávala (C') po úpravě (ADJ) pro
kratší návštěvy OPRP kliniky (b, c, d). Maximální náklady (CMAX) pro HRT a OPRP byly modelovány na 1 341 USD a 22 232 USD.
Fig. 1. Projected annual costs in USD for two menopause treatments, standard (Rx) hormone replacement therapy and ovarian platelet-rich plasma (P) estimated by Monte Carlo simulations (N = 500). Cumulative spend (yellow line vs. red line) for HRT was significantly below OPRP (P < 0.0001, by Student’s T-test) and persisted (C’) after adjustment (ADJ) for shorter-duration OPRP clinic visits (b, c, d). Maximum costs (CMAX) for HRT and OPRP were modeled at ,341 and ,232, respectively.
Obr. 1. Předpokládané roční náklady v USD na dvě léčby menopauzy, standardní (Rx) hormonální substituční terapii a ovariální plazmu bohatou na krevní destičky (P) odhadnuté pomocí Monte Carlo simulací (n = 500). Kumulativní útrata (žlutá čára vs. červená čára) za HRT byla významně pod OPRP (p < 0,0001, Studentovým T-testem) a přetrvávala (C') po úpravě (ADJ) pro kratší návštěvy OPRP kliniky (b, c, d). Maximální náklady (CMAX) pro HRT a OPRP byly modelovány na 1 341 USD a 22 232 USD.


Each year, about two million women enter menopause and about 40% are likely to use ‘bio­identical hormones’ to help manage their symptoms [3]. No research has focused on OPRP use speci­fically in this population, and what ancillary data are available usually appear without reference to fiscal parameters. Menopause-associated estrogen deficiency is intrinsically subjective, but vali­dated questionnaires can monitor several relevant parameters during this phase [33]. There is a nascent but enlarging body of OPRP literature investigating these topics. Genitourinary irritation, vaginal atrophy or dryness, and/or dyspareunia have a deeply personal and negative effect on women’s health and relationships, impacting at least half of all menopausal women [34]. When these symptoms were queried after OPRP, slightly more than half (41/80) noted improved vaginal lubrication/cervical mucus production with treatment [24]. Elevated arousal/sexual desire was simi­larly reported by study patients following OPRP, including ability to achieve orgasm/climax during sex (noted in 45% of patients). The report failed to speculate why patients with improved overall sexual experience were significantly older than those reporting no change (47.9 ± 6.3 vs. 43.5 ± 5.2 yrs; P = 0.001). Unfortunately, the study was also not designed to rank or sequence these improvements, or measure the duration of their perceived effects [24].

Perimenopause is frequently accompanied by increased fatigue [35,36] and self-reported ‘low energy’. How effectively this problem was managed by an ‘ovarian rejuvenation’ technique was assessed using a confidential questionnaire in 2019. Regarding daily ave­rage energy level, 45 of 80 (56.3%) experienced less fatigue after OPRP [24]. Data were also collected on skin texture/tone, nail growth, and scalp hair thickness/volume after receiving OPRP. These dermatology-related para­meters were tabulated together, and 37/80 patients (46.3%) registered cosmetic improvements after treatment, a change closely correlated with daily average energy level (Pearson’s R = 0.41;  P < 0.001) [24].

Estrogens modulate serotonin and noradrenalin balance, thereby influencing cognitive function and mood [37]. HRT in menopause is believed to lower dementia risk if implemented before symptoms begin, and thus may be safely prescribed early for women free of dementia [38]. Authors have reported conflicting data on HRT effects on cognition [39] and for OPRP it remains to be shown if this may provide useful corrections in mood, affect, or cognition. A pilot program was used to measure cognitive acuity and mentation after OPRP, with 37/80 patients (46.3%) experiencing substantially less ‘brain fog’ after the procedure [24]. Of note, improved cognitive acuity was significantly correlated with skin improvements (R = 0.36; P < 0.01) and  energy level (R = 0.47; P < 0.001). For sleep quality, 43.8% of study subjects reported this was better after OPRP. Sleep optimization often accompanied skin improvements (R = 0.42; P < 0.01), increased  energy level (R = 0.42; P < 0.01), and better mentation (R = 0.39; P < 0.01) [24].

While sleep quality, daytime fatigue, and workplace productivity share connections, precise quantification of relevant factors is complex and surprisingly difficult to study. Detailed research [40] reported unemployment risk to be > 30% higher for women with vs. without new-onset sleep disturbances. For women age 42–64 yrs in USA, annual producti­vity loss attributed to sleep disorders  exceeded $2B [40].

Greek experts [41] were able to reverse menopause in more than half (18/30) of participants receiving ‘ovarian rejuvenation’, and also documented significant improvements in antral follicle count and serum AMH. In this population of non-HRT users between ages 45–55 yrs, participants had no menses for at least 12 months before OPRP. Improved hormonal levels were verified in 24/30 patients after intraovarian PRP [41]. This aligns with data on 80 California patients (mean ± SD age 45.5 ± 6 yrs) where more than half had irregular or absent menses at baseline [24]. While return of menstruation or recovery of regu­lar menses was attained by 24% after OPRP, among those using HRT before enrollment, most (31/46) were able to stop all hormone use following OPRP. For sexually active patients (86%), only three reported reduced sexual activity after OPRP (4.4%). It was also possible to assess improvement (27.3%) vs. impairment (4.4%) in sexual activity after ‘ovarian rejuvenation’, and the diffe­rence favoring OPRP was highly significant (P = 0.008, by N-1 c2 test). For the 11 women not sexually active before OPRP, return of sexual activity after treatment was reported by > 25%. While no patient reported weight gain with OPRP, weight loss among patients completing OPRP was small but significant [24].  Vasomotor symptoms were also eva­luated following OPRP, with significant improvement in ‘hot flashes’ reported 14wks after treatment [42].

Our audit of menopausal OPRP use has at least two limitations:

1) Provisional calculations from statistical modeling can be eclipsed by clinical/actuarial data (when available).

2) Published ‘ovarian rejuvenation’ protocols show that platelet activation and specimen processing remain to be harmonized.

Neither problem confronts HRT, and indeed some common elements exist which make comparison easier. For  example, the basic clinical appointment required to obtain either treatment (HRT or OPRP) is the same, between $75–$200. Before determining any treatment, the physician is likely to perform an  examination and obtain tests to assess hormone levels [43].

It should be noted that many U.S. health insurance plans have at least one HRT option on formulary, but sometimes cover is refused on the basis that treating menopause is a personal choice – using a taxonomy where menopause is not a true disease state, but rather ‘a normal part of aging’ [43]. Not every patient responds to HRT satisfactorily and this is surely true for OPRP, as well. Surprisingly little is known about the proportion of refractory HRT cases although the menu of available HRT delivery systems disfavors OPRP – which, for now, is essentially non-diversified. A condensed plasma cytokine PRP variant has been successfully used for ovaries [44] but not speci­fically for menopause, so more research is needed.

Because OPRP is a much newer treatment modality, it suffers from wide cost fluctuations commonly seen with novel­ty procedures. But as efficiencies improve, it is possible OPRP costs will stabilize at lower levels to bring the treatment within reach for more patients. The difference between HRT and OPRP dose schedule is also noteworthy: Months can pass between ‘ovarian rejuvenation’ visits whereas HRT must be replaced/refilled on a monthly, weekly, or every-other-day basis. The 4-month dosing pattern used here was based on feedback shared by California patients; lasting effects of OPRP could be more durable and allow less frequent ‘booster’ visits. Yet, any advantage from eliminating HRT pharmacy refills is obviated (dwarfed, even) by the dramatically higher cost of OPRP, even if the latter involved only a single yearly visit. Because some clinics provide ‘ovarian rejuvenation’ with anesthesia – a variable our formula omitted – OPRP could be even more expensive than estimated here.

Consumer preference for ‘bio­identicals’ shows how dissatisfaction can drive new demand, even when the new item costs more. Perhaps the simplest explanation for the superiority of HRT identified here is the crushing inefficiency of OPRP when structured as a ‘subscription service’. Success with OPRP has showcased its role in ovarian reserve upticks, over months or weeks, to optimize response to gonadotropin treatments for IVF. When this enables unassisted pregnancy [41,44,45], the investment in OPRP is recompensed by avoiding costs of IVF. Quality-of-life gains or menopause reversal after OPRP while awaiting IVF, although welcome and never trivial, are best marked as incidental objectives. Thus, repurposing OPRP for nonreproductive use appears work­able only if its significantly higher cost brings consistent benefits not attainable with simpler and cheaper HRT. Improved ovarian capacity, sexual health, and metabolism with OPRP may suggest applications outside fertility practice, but the commercial dominance of standard HRT seems secure. The convenience and low cost of HRT will be difficult, if not impossible, for OPRP to overcome. The subject warrants further study especially given the ever-growing number of menopausal patients.

ORCID number:

E. Scott Sills 0000-0001-7334-1031

S. L. Tan 0000-0001-5311-1255

Submitted/Doručeno: 3. 11. 2021

Accepted/Přijato: 14. 12. 2021

Eric Scott Sills, MD, PhD

Reproductive Research Section


Box 73910, San Clemente

California 92673



1. Marjoribanks J, Farquhar C, Roberts H et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2017; 1 (1): CD004143. doi: 10.1002/14651858.CD004143.pub5.

2. Thaung Zaw JJ, Howe PR, Wong RH. Postmenopausal health interventions: time to move on from the Women’s Health Initiative? Ageing Res Rev 2018; 48: 79–86. doi: 10.1016/j.arr.2018.10.005.

3. Donovitz GS. Society position statements on bio­-identical hormones-misinformation leads to a dilemma in women’s health. Healthcare (Basel) 2021; 9 (7): 782. doi: 10.3390/healthcare9070 782.

4. Majumdar SR, Almasi EA, Stafford RS. Promotion and prescribing of hormone therapy after report of harm by the Women’s Health  Initiative. JAMA 2004; 292 (16): 1983–1988. doi: 10.1001/jama.292.16.1983.

5. Hing E, Brett KM. Changes in U.S. prescribing patterns of menopausal hormone therapy, 2001–2003. Obstet Gynecol 2006; 108 (1): 33–40. doi: 10.1097/01.AOG.0000220502.77153.5a.

6. Krzyżanowska M, Górecka K. Women‘s know­ledge on the menopausal transition in relation to their socio-economic status. Prz Menopauzalny 2021; 20 (2): 81–87. doi: 10.5114/pm. 2021.106891.

7. Vance DA. Premarin: the intriguing history of a controversial drug. Int J Pharm Compd 2007; 11 (4): 282–286.

8. Santoro N, Liss J. Compounded bio­identical hormones: myths and realities. Clin Obstet Gynecol 2021; 64 (4): 793–802. doi: 10.1097/ GRF.0000000000000650.

9. Pantos K, Nitsos N, Kokkali G et al. Ovarian rejuvenation and folliculogenesis reactivation in peri-menopausal women after auto­logous platelet-rich plasma treatment [abstract]. Hum Reprod 2016; Suppl: P401. Available from: https: // assets/docs/111052.pdf.

10. Sfakianoudis K, Simopoulou M, Nitsos N et al. Autologous platelet-rich plasma treatment enables pregnancy for a woman in premature menopause. J Clin Med 2018; 8 (1): 1. doi: 10.3390/jcm8010001.

11. Farimani M, Heshmati S, Poorolajal J et al. A report on three live births in women with poor ovarian response following intra-ovarian injection of platelet-rich plasma (PRP). Mol Biol Rep 2019; 46 (2): 1611–1616. doi: 10.1007/s11033-019-04609-w.

12. Pantos K, Simopoulou M, Pantou A et al. A case series on natural conceptions resulting in ongoing pregnancies in menopausal and prematurely menopausal women following platelet-rich plasma treatment. Cell Transplant 2019; 28 (9–10): 1333–1340. doi: 10.1177/0963689719859539.

13. Morris E, Currie H. UK HRT shortages, how can this be good for anybody? Post Reprod Health 2020; 26 (1): 3–4. doi: 10.1177/2053 369120910693.

14. Chalouhi S. Menopause: a complex and controversial journey. Post Reprod Health 2017; 23 (3): 128–131. doi: 10.1177/2053369117711346.

15. Cumming GP, Currie H, Morris E et al. The need to do better – are we still letting our patients down and at what cost? Post Reproductive Health 2015; 21 (2): 56–62. doi: 10.1177/2053369115586122.

16. Latalski M, Walczyk A, Fatyga M et al. Allergic reaction to platelet-rich plasma (PRP): case report. Medicine (Baltimore) 2019; 98 (10): e14702. doi: 10.1097/MD.0000000000014702.

17. McPherson T, Fontane P, Bilger R. Patient experiences with compounded medications. J Am Pharm Assoc (2003) 2019; 59 (5): 670.e2–677.e2. doi: 10.1016/j.japh.2019.05.005.

18. Huntley AL. Compounded or confused? Bioidentical hormones and menopausal health. Menopause Int 2011; 17 (1): 16–18. doi: 10.1258/mi.2011.011009.

19. Atkinson L, Martin F, Sturmey RG. Intraovarian injection of platelet-rich plasma in assisted reproduction: too much too soon? Hum Reprod 2021; 36 (7): 1737–1750. doi: 10.1093/ humrep/deab106.

20. Sills ES, Rickers NS, Petersen JL et al. Rege­nerative effect of intraovarian injection of autologous platelet rich plasma: serum anti-Mullerian hormone levels measured among poor-prognosis in vitro fertilization patients. Int J Regenerative Med 2020; 3: 1–5. doi: 10.31487/j.RGM.2020.01.02.

21. Ahmadian S, Sheshpari S, Pazhang M et al. Intra-ovarian injection of platelet-rich plasma into ovarian tissue promoted rejuvenation in the rat model of premature ovarian insufficiency and restored ovulation rate via angiogenesis modulation. Reprod Biol Endocrinol 2020; 18 (1): 78. doi: 10.1186/s12958-020-00638-4.

22. Cagnacci A, Venier M. The controversial history of hormone replacement the­rapy. Medicina (Kaunas) 2019; 55 (9): 602. doi: 10.3390/medicina55090602.

23. Rozenberg S, Al-Daghri N, Aubertin-Leheudre M et al. Is there a role for menopausal hormone therapy in the management of postme­nopausal osteoporosis? Osteoporosis Int 2020; 31 (12): 2271–2286. doi: 10.1007/s00198-020-05 497-8.

24. Sills ES, Li X, Rickers NS et al. Metabolic and neurobehavioral response following intraovarian administration of autologous activated platelet rich plasma: first qualitative data. Neuro Endocrinol Lett 2019; 39 (6): 427–433. Avail­able from: https: //

25. Allied Market Research. HRT market analysis. 2021 [online]. Available from: https: //

26. Sills ES, Wood SH. Progress in human ovarian rejuvenation: current platelet-rich plasma and condensed cytokine research activity by scope and international origin. Clin Exp Reprod Med 2021; 48 (4): 311–315. doi: 10.5653/cerm.2021.04651.

27. Masler S, Strickland RR. The role of mana­gement in an in vitro fertilization practice. Semin Reprod Med 2013; 31 (3): 204–210. doi: 10.1055/s-0033-1336601.

28. Sheyn D, Mahajan S, Billow M et al. Geographic variance of cost associated with hyste­rectomy. Obstet Gynecol 2017; 129 (5): 844–853. doi: 10.1097/AOG.0000000000001966.

29. Samsioe G, Dvorak V, Genazzani AR et al. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women. Maturitas 2007; 57 (2): 171–181. doi: 10.1016/j.maturitas.2007.01.001.

30. Chang CY, Tsai FJ, Chiou JS et al. Timing and dosage of and adherence to hormone replacement therapy and fracture risk in women with menopausal syndrome in Taiwan: a nested case-control study. Maturitas 2021; 146: 1–8. doi: 10.1016/j.maturitas.2020.12.010.

31. Storrs C. Is platelet-rich plasma an effective healing therapy? Sci Am 2009 [online]. Available from: https: //

32. U.S. inflation calculator. 2021 [online]. Available from: https: //

33. Sourouni M, Zangger M, Honermann L et al. Assessment of the climacteric syndrome: a narrative review. Arch Gynecol Obstet 2021; 304 (4): 855–862. doi: 10.1007/s00404-021-06139-y.

34. Marino JM. Genitourinary syndrome of  menopause. J Midwifery Womens Health 2021; 66 (6): 729–739. doi: 10.1111/jmwh.13277.

35. Kalmbach DA, Cheng P, Arnedt, JT et al. Improving daytime functioning, work performance, and quality of life in postmenopausal women with insomnia: comparing cognitive behavioral therapy for insomnia, sleep restriction therapy, and sleep hygiene education. J Clin Sleep Med 2019; 15 (7): 999–1010. doi: 10.5664/jcsm.7882.

36. Chiu HH, Tsao LI, Liu CY et al. The perimenopausal fatigue self-management scale is suitable for evaluating perimenopausal Taiwanese women’s vulnerability to fatigue syndrome. Healthcare (Basel) 2021; 9 (3): 336. doi: 10.3390/healthcare9030336.

37. Birkhäuser M. Climacteric depression and anxiety. Ther Umsch 2021; 78 (8): 427–434. doi: 10.1024/0040-5930/a001293.

38. Stute P, Wienges J, Koller AS et al. Cognitive health after menopause: does menopausal hormone therapy affect it? Best Pract Res Clin Endocrinol Metab 2021; 35 (6): 101565. doi: 10.1016/j.beem.2021.101565.

39. Conde DM, Verdade RC, Valadares AL et al. Menopause and cognitive impairment: a narrative review of current knowledge. World J Psychiatry 2021; 11 (8): 412–428. doi: 10.5498/wjp.v11.i8.412.

40. Kagan R, Shiozawa A, Epstein AJ et al. Impact of sleep disturbances on employment and work productivity among midlife women in the US SWAN database: a brief report. Menopause 2021; 28 (10): 1176–1180. doi: 10.1097/GME. 0000000000001834.

41. Sfakianoudis K, Simopoulou M, Grigoriadis S et al. Reactivating ovarian function through autologous platelet-rich plasma intraovarian infusion: pilot data on premature ovarian insufficiency, perimenopausal, menopausal, and poor responder women. J Clin Med 2020; 9 (6): 1809. doi: 10.3390/jcm9061809.

42. Merhi Z, Seckin S, Mouanness M. Intraovarian PRP injection improved hot flashes in a woman with very low ovarian reserve. Reprod Sci 2021; 29 (2): 614–619. doi: 10.1007/ s43032-021-00655-7.

43. Hormone replacement therapy cost. Cost Helper Health 2021 [online]. Available from: https: //

44. Sills ES, Rickers NS, Wood SH. Intraovarian insertion of autologous platelet growth factors as cell-free concentrate: fertility recovery and first unassisted conception with term delivery at age over 40. Int J Reprod Biomed 2020; 18 (12): 1081–1086. doi: 10.18502/ijrm.v18i12.8030.

45. Petryk N, Petryk M. Ovarian rejuvenation through platelet-rich autologous plasma (PRP) – a chance to have a baby without donor eggs, improving the life quality of women suffering from early menopause without synthetic hormonal treatment. Reprod Sci 2020; 27 (11): 1975–1982. doi: 10.1007/s43032-020-00266-8.

Dětská gynekologie Gynekologie a porodnictví Reprodukční medicína

Článek vyšel v časopise

Česká gynekologie

Číslo 1

2022 Číslo 1

Nejčtenější v tomto čísle
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.


Nemáte účet?  Registrujte se